Please check your internet connection and try again.
# Sodium Phosphate Enema
## Overview
Sodium phosphate enema is a hypertonic saline solution that acts as an osmotic laxative by drawing water into the colon, increasing intraluminal pressure and stimulating bowel motility.
## Primary Indications
Bowel preparation for diagnostic procedures (e.g., colonoscopy, sigmoidoscopy) and surgical procedures.
Treatment of constipation.
## Adult Dosing
* **Bowel Preparation:** Typically, one 4.5 oz (133 mL) enema administered 3-5 hours before the procedure. A second dose may be administered if recommended by local protocol or physician.
* **Constipation:** One 4.5 oz (133 mL) enema as a single dose. Do not administer more than one enema in a 24-hour period.
## Pediatric Dosing
Dosing is not well-established for routine use in children. Use with extreme caution and only under strict medical supervision. Smaller volumes may be used based on age and weight, but this requires specific physician guidance and adherence to local protocols.
## Dose Adjustments
No specific dose adjustments are generally recommended for renal or hepatic impairment, but caution is advised due to the risk of electrolyte disturbances.
## Contraindications
* Congestive heart failure
* Acute renal failure
* Children under 2 years of age
* Congenital megacolon
* Intestinal obstruction
* Perforated bowel
* Gastroenteritis
* Other conditions where increased laxative use is contraindicated
* Patients with decreased rectal sensitivity or inability to retain the enema
## Adverse Effects
Common: Abdominal cramping, bloating, nausea, vomiting, rectal irritation.
Serious: Electrolyte imbalances (hyperphosphatemia, hypocalcemia, hypernatremia, hypokalemia), dehydration, cardiac arrhythmias, renal failure (especially with overuse or in susceptible individuals), hypersensitivity reactions.
## Key Drug Interactions
* **Diuretics:** Increased risk of electrolyte imbalances.
* **ACE inhibitors and ARBs:** Increased risk of hyperkalemia.
* **Calcium-containing medications:** Potential for hypercalcemia, especially with frequent use.
* **Drugs affecting renal function:** Increased risk of acute kidney injury.
## Monitoring
* Monitor for signs and symptoms of dehydration and electrolyte imbalances (e.g., thirst, dry mouth, decreased urine output, muscle cramps, weakness, dizziness, confusion, irregular heartbeat).
* Renal function (BUN, creatinine) and electrolytes (sodium, potassium, phosphate, calcium) should be monitored, particularly in patients with pre-existing renal disease, heart failure, or those receiving other medications that affect electrolytes.
## Clinical Pearls
* Administer slowly and retain for 5-15 minutes or as long as possible.
* Avoid use in patients at risk for fluid and electrolyte disturbances.
* The risk of serious adverse events, including acute phosphate nephropathy and severe electrolyte disturbances, is increased with overuse, concurrent use of other laxatives, or in patients with underlying conditions.
* Ensure adequate hydration before and after administration.
---
*This information is intended for clinical use and does not replace comprehensive drug information resources. Always verify current prescribing information with the official product labeling or a trusted drug information database.*
